Inventor · disambiguated record
Billy G. Hudson
Also filed as: HUDSON BILLY · HUDSON BILLY G
31 granted patents·19 pending applications·801 citations·filing 1990–2016
98Inventor score
Files withUNIV KANSAS MEDICAL CENTER18KANSAS UNIVERSITY MEDICAL CT13UNIV VANDERBILT8UNIV YALE3VANDERBILT UNIVERSITY CT FOR TECHNOLOGY TRANSFER AND COMMERCIALIZATION3
Top patents by PatentIndex Score
50 records- 0195US7030146B2Methods for treating diabetic neuropathyKANSAS UNIVERSITY MEDICAL CT·Filed 2003·Granted Apr 18, 2006·270 cites·2 claims
- 0291US6436969B1Dialysis solutions and methodsKANSAS UNIVERSITY MEDICAL CT R·Filed 2000·Granted Aug 20, 2002·48 cites·2 claims
- 0390US6361994B1Method for inhibiting angiogenesis and tumors with the isolated NC1 α1 chain monomer of type IV collagenUNIV KANSAS MEDICAL CENTER·Filed 2000·Granted Mar 26, 2002·20 cites·3 claims
- 0487US6750209B1Advanced glycation end-product intermediaries and post-amadori inhibitionKANSAS UNIVERSITY MEDICAL CT·Filed 2000·Granted Jun 15, 2004·29 cites·3 claims
- 0585US6472411B1Advanced glycation end-product intermediaries and post-amadori inhibitionUNIV KANSAS MEDICAL CENTER·Filed 2000·Granted Oct 29, 2002·19 cites·4 claims
- 0685US5985857AAdvanced glycation end-product intermediaries and post-amadori inhibitionKANSAS UNIVERSITY MEDICAL CENT·Filed 1996·Granted Nov 16, 1999·59 cites·20 claims
- 0783US6432706B1Method for inhibiting angiogenesis and tumors with the isolated NC1 α6 chain monomer of type IV collagenUNIV KANSAS MEDICAL CENTER·Filed 2000·Granted Aug 13, 2002·6 cites·16 claims
- 0880US6521645B2Methods for the treatment and prevention of urinary stone diseaseUNIV KANSAS MEDICAL CENTER·Filed 2001·Granted Feb 18, 2003·18 cites·22 claims
- 0980US6419924B1Antibodies of isolated domains of type IV collagen modify cell interactionsUNIV KANSAS MEDICAL CENTER·Filed 2000·Granted Jul 16, 2002·3 cites·12 claims
- 1080US5567609AUse of isolated domains of type IV collagen to modify cell and tissue interactionsUNIV KANSAS MEDICAL CENTER·Filed 1994·Granted Oct 22, 1996·36 cites·3 claims
- 1179US6689746B2Use of isolated domains of type IV collagen to modify cell and tissue interactionsKANSAS UNIVERSITY MEDICAL CT·Filed 2002·Granted Feb 10, 2004·3 cites·3 claims
- 1279US5691182AUse of isolated domains of type IV collagen to modify cell and tissue interactionsUNIV KANSAS MEDICAL CENTER·Filed 1995·Granted Nov 25, 1997·20 cites·4 claims
- 1378US6358735B1Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagenUNIV KANSAS MEDICAL CENTER·Filed 2000·Granted Mar 19, 2002·5 cites·3 claims
- 1476US6448222B1Use of isolated alpha 2 domain of type IV collagen to modify cell and tissue interactionsUNIV KANSAS MEDICAL CENTER·Filed 2000·Granted Sep 10, 2002·3 cites·8 claims
- 1576US6277558B1α-3 chain type IV collagen polynucleotidesKANSAS UNIVERSITY MEDICAL CT·Filed 1999·Granted Aug 21, 2001·42 cites·7 claims
- 1674US5856184AIsolated domains of type IV collagen to modify cell and tissue interactionsUNIV KANSAS MEDICAL CENTER·Filed 1997·Granted Jan 5, 1999·24 cites·4 claims
- 1773US6228858B1Advanced glycation end-product intermediaries and post-amadori inhibitionUNIV KANSAS MEDICAL CENTER·Filed 1997·Granted May 8, 2001·24 cites·13 claims
- 1872US6498140B1Use of isolated domains of type IV collagen to modify cell and tissue interactionsUNIV KANSAS MEDICAL CENTER·Filed 2000·Granted Dec 24, 2002·1 cites·4 claims
- 1972US5424408Aα-3 chain type IV collagen polynucleotidesUNIV YALE·Filed 1990·Granted Jun 13, 1995·28 cites·4 claims
- 2069US5973120Aα-3 chain type IV collagen polypeptidesUNIV YALE·Filed 1995·Granted Oct 26, 1999·17 cites·3 claims
- 2168US2005004033A1Use of isolated domains of type IV collagen to modify cell and tissue interactionKANSAS UNIVERSITY MEDICAL CT·Filed 2004·Application pending·0 cites
- 2267US7122517B2Crystallized structure of type IV collagen NC1 domain hexamerKANSAS UNIVERSITY MEDICAL CT·Filed 2002·Granted Oct 17, 2006·6 cites·9 claims
- 2367US6007980AAlpha-3 chain type IV collagen polypeptidesUNIV YALE·Filed 1998·Granted Dec 28, 1999·18 cites·7 claims
- 2467US2004132662A1Use of isolated domains of type IV collagen to modify cell and tissue interactionKANSAS UNIVERSITY MEDICAL CT·Filed 2003·Application pending·0 cites
- 2566US6472400B1Advanced gylcation end-product intermediaries and post-Amadori inhibitionUNIV KANSAS MEDICAL CENTER·Filed 1999·Granted Oct 29, 2002·16 cites·4 claims
- 2666US2013065929A1Use of Pyridoxamine to Treat and/or Prevent Disease ProcessesUNIV VANDERBILT·Filed 2012·Application pending·0 cites
- 2763US6680293B2Use of isolated domains of type IV collagen to modify cell and tissue interactionsUNIV KANSAS MEDICAL CENTER·Filed 2002·Granted Jan 20, 2004·0 cites·6 claims
- 2863US2009221650A1Use of Pyridoxamine to Treat and/or Prevent Disease ProcessesHUDSON BILLY G·Filed 2008·Application pending·0 cites
- 2962US2014296303A1Use of Pyridoxamine to Treat and/or Prevent Disease ProcessesUNIV VANDERBILT·Filed 2014·Application pending·0 cites
- 3059US9289417B2Compounds and methods for the modulation of sulfilimine bond formationHUDSON BILLY G·Filed 2010·Granted Mar 22, 2016·1 cites·6 claims
- 3159US6730686B1Methods for inhibiting oxidative modification of proteinsKANSAS UNIVERSITY MEDICAL CT·Filed 1999·Granted May 4, 2004·25 cites·7 claims
- 3258US6740668B1Methods for inhibiting diabetic complicationsKANSAS UNIVERSITY MEDICAL CT·Filed 1999·Granted May 25, 2004·23 cites·8 claims
- 3358US6716858B1Methods for inhibiting diabetic complicationsKANSAS UNIVERSITY MEDICAL CT·Filed 1999·Granted Apr 6, 2004·20 cites·18 claims
- 3458US2014296302A1Methods For Treating InflammationVANDERBILT UNIVERSITY CT FOR TECHNOLOGY TRANSFER AND COMMERCIALIZATION·Filed 2014·Application pending·0 cites
- 3557US6440729B1Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagenUNIV KANSAS MEDICAL CENTER·Filed 1999·Granted Aug 27, 2002·10 cites·2 claims
- 3657US2014080874A1Methods For Treating InflammationVANDERBILT UNIVERSITY CT FOR TECHNOLOGY TRANSFER AND COMMERCIALIZATION·Filed 2013·Application pending·0 cites
- 3757US2007155801A1Advanced glycation end-product intermediaries and post-amadori inhibitionUNIV KANSAS MEDICAL CENTER·Filed 2007·Application pending·0 cites
- 3856US6384012B1Use of isolated domains of type IV collagen to modify cell and tissue interactionsUNIV KANSAS MEDICAL CENTER·Filed 1998·Granted May 7, 2002·7 cites·12 claims
- 3956US2010240710A1Use of Pyridoxamine to Treat and/or Prevent Disease ProcessesUNIV VANDERBILT·Filed 2010·Application pending·0 cites
- 4054US2013017616A1Methods For Treating InflammationVANDERBILT UNIVERSITY CT FOR TECHNOLOGY TRANSFER AND COMMERCIALIZATION·Filed 2012·Application pending·0 cites
- 4152US2007238761A1Use of pyridoxamine to treat and/or prevent disease processesUNIV VANDERBILT·Filed 2006·Application pending·0 cites
- 4250US2004220090A1Advanced glycation end-product intermediaries and post-amadori inhibitionKANSAS UNIVERSITY MEDICAL CT·Filed 2004·Application pending·0 cites
- 4349US2003013746A1Advanced glycation end-product intermediaries and post-amadori inhibitionUNIV KANSAS MEDICAL CENTER·Filed 2002·Application pending·0 cites
- 4448US10183039B2Methods for the production of collagen IVUNIV VANDERBILT·Filed 2014·Granted Jan 22, 2019·0 cites·16 claims
- 4548US2003060490A1Method for the treatment and prevention of urinary stone diseaseFiled 2002·Application pending·0 cites
- 4647US2003017995A1Dialysis solutions and methodsKANSAS UNIVERSITY MEDICAL CT·Filed 2002·Application pending·0 cites
- 4746US2007042965A1Crystallized structure of type IV collagen NC1 domain hexamerKANSAS UNIVERSITY MEDICAL CT·Filed 2006·Application pending·0 cites
- 4842US2017042869A1Methods for limiting acute kidney injuryUNIV VANDERBILT·Filed 2016·Application pending·0 cites
- 4940US2016128992A1Methods for limiting acute kidney injuryUNIV VANDERBILT·Filed 2015·Application pending·0 cites
- 5031US2018055913A1Recombinant collagen iv surrogates and uses thereofUNIV VANDERBILT·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Billy G. Hudson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →